If you hold ARK Innovation ETF (NYSEARCA:ARKK) and think the bad news is behind you, look again at the fee line. ARKK quietly charges 0.75% a year on roughly $7.2 billion in assets, then routes that money into a 46-stock bet that has trailed cheaper funds by a country mile.
What you are actually paying
The headline cost is simple. ARKK’s expense ratio of 0.75% equals $75 per year for every $10,000 invested. A passive Nasdaq fund like Invesco QQQ Trust (NASDAQ:QQQ) charges roughly 20 basis points, or about $20 per $10,000. The gap, $55 a year, sounds trivial. Compounded over decades, it carves a real hole in returns.
Over 20 years, that fee differential alone can quietly skim thousands off a five-figure account, before you account for what the fund actually returned. And the returns are where the bill gets ugly. Over the past five years, ARKK has lost 37.88% while QQQ gained 103.96% and SPDR S&P 500 ETF Trust (NYSEARCA:SPY) gained 72.6%. Even over the past year, ARKK’s 11.47% gain trailed QQQ’s 34.23%. You paid premium fees for discount results.
The part the factsheet does not highlight
ARKK’s portfolio is built for turnover. The fund holds 46 positions, with Tesla alone at 9.735% of assets, Tempus AI at 5.356%, AMD at 5.184%, and CRISPR Therapeutics at 4.980%. Cathie Wood’s recent trading log shows constant rebalancing: a $529.7 million SpaceX buy on June 15, a $99 million Alphabet buy on June 7, a $16.2 million Tesla sale on June 13. Every trade prints a spread cost and can generate taxable gains the prospectus does not warn you about line by line.
There is also a liquidity tax. ARKK now owns OpenAI Group PBC Series C at $174,999,811.56, or 2.699% of assets, plus Brera Holdings warrants and stakes in micro-cap biotech and crypto-adjacent names like CoreWeave and Bullish. Private equity and warrants do not trade like Amazon. When the manager has to mark them or move them, the cost shows up inside NAV, not on the fee schedule.
Investors are noticing. ARKK has bled $313 million in outflows year to date, even as one Benzinga headline put it, the fund “Trails S&P 500, Nasdaq 100 By Far.”
The cheaper mirror
Two alternatives sit in plain sight. QQQ delivers concentrated mega-cap tech exposure for a fraction of ARKK’s fee, and over the past decade it has returned 584.29% versus ARKK’s 337.82%. For investors who want a quality screen instead of a thematic bet, VanEck Morningstar Wide Moat ETF (NYSEARCA:MOAT) gained 45% over five years while ARKK lost 33%, with roughly half the volatility. The trade-off is real: you give up exposure to genomics microcaps, private AI plays, and crypto infrastructure. The question is whether that exposure has earned its keep.
What this means for you
ARKK’s pitch is conviction. The receipt is a 0.75% annual fee, turnover-driven trading costs, and illiquid private positions wrapped in a daily-traded ETF. The retail crowd on r/wallstreetbets still calls it “terrible meme stuff” and stays bullish anyway. Before you do the same, ask the question the marketing avoids: what specific exposure am I getting here that I cannot buy for 20 basis points somewhere else, and has it actually paid me for the risk?
Top Gaining Stocks
Top Losing Stocks